#USA #Alzheimer's #Fremont, California #Alamar Biosciences #NULISAqpcr

Alamar Biosciences Launches Revolutionary NULISAqpcr™ BD-pTau217 Assay

Alamar Biosciences has recently made a significant advancement in Alzheimer’s research with its newly launched NULISAqpcr™ BD-pTau217 assay. This innovative blood test enables the non-invasive quantification of pTau217, a crucial biomarker linked to Alzheimer’s and other tauopathies, setting a new standard for precision and specificity in neurodegenerative disease research.

What Makes NULISAqpcr™ BD-pTau217 Unique?

The NULISAqpcr BD-pTau217 assay is the only single-plex solution available for brain-derived tau measurement. This assay establishes new benchmarks for accuracy and specificity when conducting research into central nervous system (CNS) diseases. The assay allows researchers to quantify levels of pTau217 in non-invasive samples such as plasma, serum, and dried blood spots, overcoming previous barriers that required cerebrospinal fluid (CSF) collection or PET imaging.

Dr. Yuling Luo, founder and CEO of Alamar Biosciences, emphasized that this assay redefines biomarker quantification capabilities for the CNS. By filtering out extraneous sources of tau from the periphery, researchers are now equipped to detect meaningful changes in brain health with unprecedented precision and earlier timing.

Expert Validation and Implications

Jonathan Schott, MD, PhD, a professor of Neurology at University College London, praised the performance of the pTau217 assays, noting that preliminary results indicate the single-plex format performs well compared to established plasma tests while showing greater variability. This marks a substantial advantage as it minimizes samples classified as indeterminate. The prospect of utilizing brain-specific pTaus measured through the multiplexing assay is promising for identifying asymptomatic individuals with advanced Alzheimer pathology, who may be candidates for disease-modifying therapies.

Streamlined Research Workflow

Available as either a single-plex assay or as part of the NULISAseq™ CNS Disease Panel 120 multiplexing set, the BD-pTau217 assay is positioned to facilitate both discovery and translational research endeavors. The automated workflow associated with the ARGO™ HT system allows for processing over 220 samples daily, ideally suited for high-throughput analysis in disease cohorts or population studies.

Commitment to Neuro Science Research

Alamar Biosciences is devoted to collaborating with the neuroscience community to identify new biomarkers that will accelerate the progress in Alzheimer's research and other related diseases. Through cutting-edge technology and a commitment to scientific advancement, Alamar aims to facilitate the early detection of diseases and their effective management.

More information on the NULISAqpcr™ BD-pTau217 assay can be found on Alamar Biosciences' official website. It's important to note that these assays are intended for research use only and are not to be utilized for diagnostic procedures.

About Alamar Biosciences

Alamar Biosciences is a private life sciences company dedicated to advancing precision proteomics for the early detection of diseases. Their patented NULISA™ platform and ARGO™ HT system align with the latest genomic advancements, achieving attomolar detection sensitivity well beyond any existing protein detection technologies currently on the market. To learn more, visit alamarbio.com.